Sanofi-aventis, one of the world’s largest diversified healthcare companies, reports earnings for the second-quarter of 2009. CEO Chris Viehbacher comments on Q2 earnings and the Transforming Programme.
Use these links to watch the video interview in the format of your choice:
Windows Media Player:
http://www.eurobusinessmedia.com/interviewWmp.php?id_article=468
Flash Player:
http://www.eurobusinessmedia.com/interviewFlash.php?id_article=468
Use this link to read the interview transcript:
http://www.eurobusinessmedia.com/transcript.php?id_article=468
Topics covered in the interview include:
| - Comments on Q2 earnings |
| - 8-month progress report |
| - Transforming Program |
| - Update on Lantus |
| - Multaq launch in the US |
| - Update on R&D |
| - H1N1 vaccine production |
| - Impact of H1N1 on earnings |
|
- Shantha Biotechnics acquisition |
| - Revision of 2009 EPS guidance |
| - Message to employees |
About Sanofi-aventis:
Sanofi-aventis, a leading global diversified healthcare company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT : SAN) and in New York (NYSE : SNY).
Company website: http://en.sanofi-aventis.com/home.asp
Sanofi-aventis
Investor Relations :
IR@sanofi-aventis.com
or
Media
Relations :
MR@sanofi-aventis.com
